Usefulness of a red chromagen in the diagnosis of melanocytic lesions of the conjunctiva

JAMA Ophthalmology

Volumn 132, Issue 5, 2014, Pages 622-629

  Jiang, Kailun ^a,b,c   Brownstein, Seymour ^a,b,c   Lam, Kay ^a,b,c   Burns, Bruce ^b   Farmer, James ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGENIC SUBSTRATE; DIAMINOBENZIDINE; HUMAN MELANOMA BLACK 45; HYDROGEN PEROXIDE; KI 67 ANTIGEN; MELAN A; PROTEIN; PROTEIN S 100; RED CHROMAGEN; UNCLASSIFIED DRUG; VECTOR RED;

ADULT; AGED; ANTIBODY LABELING; ANTIGENICITY; ARTICLE; BLEACHING; CHOROID; CHOROID MELANOMA; CLINICAL ARTICLE; CONJUNCTIVA; CONJUNCTIVA DISEASE; CONJUNCTIVA NEVUS; CONJUNCTIVAL MELANOCYTIC LESION; CONJUNCTIVAL MELANOMA; CONTROLLED STUDY; DOUBLE PANMELANOMA COCKTAIL; FEMALE; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOREACTIVITY; MALE; MELANOCYTE; MELANOMA; MELANOSIS; PATHOLOGIST; PRIMARY ACQUIRED MELANOSIS; PRIORITY JOURNAL; PTERYGIUM; SENSITIVITY AND SPECIFICITY; STAINING; UVEA; UVEA MELANOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CONJUNCTIVA; CONJUNCTIVAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 84900449446     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.8216     Document Type: Article

References (35)

1. Paridaens AD,Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78(4):252-259.
2. Folberg R, McLean IW, Zimmerman LE. Conjunctival melanosis and melanoma. Ophthalmology. 1984;91(6):673-678.
3. Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Experiment Ophthalmol. 2008;36(8):786-795.
4. Gloor P, Alexandrakis G. Clinical characterization of primary acquired melanosis. Invest Ophthalmol Vis Sci. 1995;36(8):1721-1729.
5. Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol. 1985;16(2):129-135.
6. Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: experience with 311 eyes. Trans Am Ophthalmol Soc. 2007;105:61-71.
7. Ackerman AB, Sood R, KoenigM. Primary acquired melanosis of the conjunctiva is melanoma in situ. Mod Pathol. 1991;4(2):253-263.
8. Reese AB. Precancerous and cancerous melanosis. Am J Ophthalmol. 1966;61(5, pt 2):1272-1277.
9. Zimmerman LE. Criteria for management of melanosis [letter]. Arch Ophthalmol. 1966;76:307-308.
10. Zimmerman LE, Sobin LH. Histologic Typing of Tumors of the Eye and Its Adnexa. Geneva, Switzerland:World Health Organization; 1980.
11. Zembowicz A, Mandal RV, Choopong P. Melanocytic lesions of the conjunctiva. Arch Pathol Lab Med. 2010;134(12):1785-1792.
12. Kenawy N, Lake SL, Coupland SE, Damato BE. Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye (Lond). 2013;27(2):142-152.
13. Missotten GS, deWolff-Rouendaal D, de Keizer RJ. Screening for conjunctival melanoma metastasis: literature review. Bull Soc Belge Ophtalmol. 2007;(306):23-30.
14. Novais GA, Fernandes BF, Belfort RN, Castiglione E, Cheema DP, Burnier MN Jr. Incidence of melanocytic lesions of the conjunctiva in a review of 10 675 ophthalmic specimens. Int J Surg Pathol. 2010;18(1):60-63.
15. SugiuraM, Colby KA,MihmMC Jr., Zembowicz A. Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: clinicopathologic analysis of 29 cases. Am J Surg Pathol. 2007;31(2):185-192.
16. Shields CL, Shields JA, Gunduz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118(11):1497-1507.
17. Sharara NA, Alexander RA, Luthert PJ, Hungerford JL, Cree IA. Differential immunoreactivity of melanocytic lesions of the conjunctiva. Histopathology. 2001;39(4):426-431.
18. Jakobiec FA, Bhat P, Colby KA. Immunohistochemical studies of conjunctival nevi and melanomas. Arch Ophthalmol. 2010;128(2):174-183.
19. DoreyMW, Brownstein S, Faraji H, Robertson S, Prokopetz R, Jordan DR. Immunohistochemical profile and histochemical analysis of primary acquired melanosis of the conjunctiva [abstract]. Invest Ophthalmol Vis Sci. 2003;44(5):E-2427.
20. Faraji H, Brownstein S, DoreyMW, Jordan DR, Robertson S. Immunohistochemical analyses of uveal melanoma and comparison with primary acquired melanosis of the conjunctiva [abstract]. Invest Ophthalmol Vis Sci. 2004;45(5):E-1210.
21. McDonnell JM, Sun YY,Wagner D. HMB-45 immunohistochemical staining of conjunctival melanocytic lesions. Ophthalmology. 1991;98(4):453-458.
22. Chowers I, Livni N, Solomon A, et al.MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia. Br J Ophthalmol. 1998;82(11):1316-1319.
23. Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Arch Ophthalmol. 2009;127(8):964-969.
24. Keijser S, Missotten GS, Bonfrer JM, deWolff-Rouendaal D, Jager MJ, de Keizer RJ. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol. 2006;90(2):213-217.
25. Pan Melanoma + S100 (Tyrosinase + MART-1 + S100). BioCare Medicalwebsite. http://biocare.net/wp-content/uploads/213DS.pdf. Accessed September 9, 2012.
26. Polyclonal Rabbit Anti-S100 (N1573). Dako website. http://www.dako.com/ download.pdf ?objectid=105457004. Accessed September 9, 2012.
27. Albreiki DHG, Gilberg SM, Farmer JP. Conjunctival malignant melanoma: a rare variant and review of important diagnostic and therapeutic considerations. Saudi J Ophthalmol. 2012;26(2):151-156.
28. Iwamoto S, Burrows RC, Kalina RE, et al. Immunophenotypic differences between uveal and cutaneous melanomas. Arch Ophthalmol. 2002;120(4):466-470.
29. Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against Melan-A with S100 protein and HMB-45. Melanoma Res. 2000;10(4):350-354.
30. Iwamoto S, Burrows RC, Grossniklaus HE, et al. Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas. Arch Ophthalmol. 2002;120(12):1625-1629.
31. Steuhl KP, Rohrbach JM, KnorrM, Thiel HJ. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology. 1993;100(2):208-215.
32. Mooy CM, de Jong PT, Van Der Kwast TH, Mulder PG, Jager MJ, Ruiter DJ. Ki-67 immunostaining in uveal melanoma: the effect of pre-enucleation radiotherapy. Ophthalmology. 1990;97(10):1275-1280.
33. Chiquet C, Grange JD, Ayzac L, Chauvel P, Patricot LM, Devouassoux-Shisheboran M. Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas. Br J Ophthalmol. 2000;84(1):98-102.
34. Kligora CJ, Fair KP, ClemMS, Patterson JW. A comparison of melanin bleaching and azure blue counterstaining in the immunohistochemical diagnosis of malignant melanoma. Mod Pathol. 1999;12(12):1143-1147.
35. Robinson J, Faraji H, Brownstein S, et al. Alternative bleaching techniques in the immunohistochemical evaluation of melanocytic lesions of the conjunctiva and uvea [abstract]. Invest Ophthalmol Vis Sci. 2005;46:E-3358.